AU2003289631A1 - A recombinant adenovirus relating gene vaccine used to therapy and prevent alzheimers disease, and use thereof - Google Patents

A recombinant adenovirus relating gene vaccine used to therapy and prevent alzheimers disease, and use thereof

Info

Publication number
AU2003289631A1
AU2003289631A1 AU2003289631A AU2003289631A AU2003289631A1 AU 2003289631 A1 AU2003289631 A1 AU 2003289631A1 AU 2003289631 A AU2003289631 A AU 2003289631A AU 2003289631 A AU2003289631 A AU 2003289631A AU 2003289631 A1 AU2003289631 A1 AU 2003289631A1
Authority
AU
Australia
Prior art keywords
therapy
prevent
recombinant adenovirus
alzheimers disease
vaccine used
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003289631A
Other versions
AU2003289631A8 (en
Inventor
Xiaoyan Dong
Wei He
Chuan Qin
Xiaobing Wu
Jianmin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Laboratory Animal Science of CAMS
Institute of Basic Medical Sciences of CAMS
AGTC Gene Technology Co Ltd
Original Assignee
AGTC Gene Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AGTC Gene Technology Co Ltd filed Critical AGTC Gene Technology Co Ltd
Publication of AU2003289631A1 publication Critical patent/AU2003289631A1/en
Publication of AU2003289631A8 publication Critical patent/AU2003289631A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003289631A 2002-11-29 2003-12-01 A recombinant adenovirus relating gene vaccine used to therapy and prevent alzheimers disease, and use thereof Abandoned AU2003289631A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN02154703.3 2002-11-29
CNB021547033A CN100450551C (en) 2002-11-29 2002-11-29 Recombinated adeno-associated virus genes vaccine for prevention and cure of Alzheimer disease and use thereof
PCT/CN2003/001019 WO2004050876A1 (en) 2002-11-29 2003-12-01 A recombinant adenovirus relating gene vaccine used to therapy and prevent alzheimers disease, and use thereof

Publications (2)

Publication Number Publication Date
AU2003289631A1 true AU2003289631A1 (en) 2004-06-23
AU2003289631A8 AU2003289631A8 (en) 2004-06-23

Family

ID=32400078

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003289631A Abandoned AU2003289631A1 (en) 2002-11-29 2003-12-01 A recombinant adenovirus relating gene vaccine used to therapy and prevent alzheimers disease, and use thereof

Country Status (3)

Country Link
CN (1) CN100450551C (en)
AU (1) AU2003289631A1 (en)
WO (1) WO2004050876A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
JP4888876B2 (en) * 2003-06-13 2012-02-29 田平 武 Recombinant adeno-associated virus vector for the treatment of Alzheimer's disease
WO2005014041A2 (en) * 2003-07-24 2005-02-17 Novartis Ag Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
EP1828251B1 (en) * 2004-10-05 2012-09-26 Janssen Alzheimer Immunotherapy Methods and compositions for improving recombinant protein production
KR101434935B1 (en) 2005-11-30 2014-10-01 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
JP5475994B2 (en) 2005-11-30 2014-04-16 アッヴィ・インコーポレイテッド Anti-Aβ globulomer antibody, antigen-binding portion thereof, corresponding hybridoma, nucleic acid, vector, host cell, method for producing said antibody, composition comprising said antibody, use of said antibody and method of using said antibody.
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CN101392027B (en) * 2008-07-03 2012-04-25 浙江大学 Fusion protein for treating alzheimer's disease and preparation method thereof
JPWO2010050585A1 (en) * 2008-10-31 2012-03-29 ディナベック株式会社 Alzheimer's disease treatment vector
CN104744591B (en) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 Amyloid beta binding proteins
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
CN103071160A (en) * 2011-10-24 2013-05-01 四川百利药业有限责任公司 Gene vaccine for Alzheimer's disease
JP2017521092A (en) * 2014-05-16 2017-08-03 ヴィトルヴィアン バイオメディカル， インク．Ｖｉｔｒｕｖｉａｎ Ｂｉｏｍｅｄｉｃａｌ， Ｉｎｃ． Diagnostic testing and treatment / prevention of Alzheimer's disease
CN107034198B (en) 2015-07-15 2021-03-09 长春百克生物科技股份公司 Chimeric norovirus P particle and preparation and application thereof
CN105597108A (en) * 2015-12-30 2016-05-25 广州凯拓生物科技开发有限公司 Construction and application of Complexin 1/2 overexpression recombinant vector
CN113862346B (en) * 2021-09-26 2023-07-07 北京大学 Application of long-chain non-coding RNA in treatment of Alzheimer disease
CN116327904B (en) * 2022-08-02 2024-05-28 深圳源兴基因技术有限公司 Recombinant adeno-associated virus gene vaccine for treating and preventing Alzheimer disease and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
EP1404368B1 (en) * 2001-06-07 2009-12-09 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant

Also Published As

Publication number Publication date
CN1504240A (en) 2004-06-16
WO2004050876A1 (en) 2004-06-17
CN100450551C (en) 2009-01-14
AU2003289631A8 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
AU2003289631A1 (en) A recombinant adenovirus relating gene vaccine used to therapy and prevent alzheimers disease, and use thereof
AU2002319867A1 (en) Streptococcus agalactiae genome sequence, use for developing vaccines, diagnostic tools, and for identifying therapeutic targets
AU2003242504A1 (en) Therapeutic tuberculosis vaccines
HK1076110A1 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
AU2003222347A1 (en) Novel peptide derivatives, preparation and therapeutic and cosmetic application thereof
AU2003257113A1 (en) Nail care system
HK1074446A1 (en) 3-phenyl substituted pyridoindolone, preparation and therapeutic use thereof
TWI316089B (en) Capsid protein of feline calicivirus strain 431 and g1, dna fragments encoding them and immunogenic preparation comprising the same
PT1525193E (en) Acylaminothiazole derivatives, preparation and therapeutic use thereof
AU2003219057A8 (en) Recombinant drug-sensitive vaccinia virus as smallpox vaccine
AU2002258728A1 (en) Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2003222823A8 (en) Physiologically compatible, phospholipid-containing, stable and hard matrix
AU2002305151A1 (en) Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
HK1074444A1 (en) Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof
AU2003249059A8 (en) Use of vaccinia virus deleted for the e3l gene as a vaccine vector
AU2003267361A1 (en) Orthopoxvirus antigens and use thereof
AU2003273035A1 (en) Gene vaccine
AU2003214667A1 (en) Elastic ruler for herb therapy and the therapy method for disease using the same
AU2002311141A1 (en) The use of hydrochloric acid in the preparation of a medicament for the treatment of tumour
AU2003240253A1 (en) Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications
AU2002322013A1 (en) Therapeutic dna vaccination
AU2003217432A1 (en) Angiopoietin-1 in the treatment of disease
AU2003264094A1 (en) Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications
AU2003232513A1 (en) Pain receptor gene and protein

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 18, NO 29, PAGE(S) 7783 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME AGTC GENE TECHNOLOGY COMPANY LTD., APPLICATION NO. 2003289631, UNDER INID (71) CORRECT THE NAME TO READ INSTITUTE OF BASIC MEDICAL SCIENCES,CHINESE ACADEMY OF MEDICAL SCIENCES; INSTITUTE OF LABORATORY ANIMALS,CHINESE ACADEMY OF MEDICAL SCIENCES; AGTC GENE TECHNOLOGY COMPANY LTD.